Get started
Work

Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).

Year: 2019
Type: conference-abstract
DOI: 10.1200/jco.2019.37.15_suppl.2032
Authors: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Jennifer Leigh Clarke, Gavin Dunn, Michael Lim, Timothy Francis Cloughesy, Hui Kong Gan, Andrew J. Park, Paul Schwarzenberger, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Ralph Rudolph Venhaus
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, University of California, San Francisco, Washington University in St. Louis, Johns Hopkins University, Johns Hopkins Hospital, University of California, Los Angeles, Olivia Newton-John Cancer Research Institute, Ludwig Cancer Research
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: closed
OpenAlex ID: W2947439071
Cites:
Cited by: 50
Related to: 10